Elias Sanchez, MD
Family Medicine · Riverside, CANPI 1508886672
Payments from drug & device makers
Across 420 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Boehringer Ingelheim$706
- AbbVie$531
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$522
- AstraZeneca$382
- Lilly USA, LLC$343
- plus $3K from 34 others
What the payments were for
- Food & beverage$6,798100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 112 | $1,242 |
| Boehringer Ingelheim | 30 | $706 |
| AbbVie(2 entities) | 30 | $531 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 32 | $522 |
| AstraZeneca | 21 | $382 |
| Lilly USA, LLC | 15 | $343 |
| Astellas Pharma US Inc | 18 | $310 |
| Johnson & Johnson | 25 | $287 |
| Merck | 17 | $286 |
| Corcept Therapeutics | 13 | $248 |
| Amarin Pharma, Inc. | 15 | $209 |
| Abbott | 11 | $200 |
| Amgen | 8 | $172 |
| Pfizer | 8 | $134 |
| Novartis | 6 | $112 |
| GSK | 4 | $108 |
| E.r. Squibb & Sons, L.L.C. | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Dexcom, Inc. | 4 | $85 |
| Vyera Pharmaceuticals, LLC | 4 | $74 |
| Sanofi Pasteur Inc. | 3 | $63 |
| Esperion Therapeutics, Inc. | 4 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $54 |
| Bayer | 2 | $51 |
| Eisai Inc. | 2 | $40 |
| Supernus Pharmaceuticals, Inc. | 3 | $38 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Ironwood Pharmaceuticals, Inc | 2 | $37 |
| Redhill Biopharma Inc. | 2 | $35 |
| Exact Sciences | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $34 |
| Ardelyx, Inc. | 1 | $32 |
| Aimmune Therapeutics, Inc. | 1 | $27 |
| Mannkind Corporation | 1 | $24 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $20 |
| Bausch Health US, LLC | 1 | $19 |
| Optos, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $17 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$6,804 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pyrimethamine | 19 | $304,839 |
| JardianceEmpagliflozin | 111 | $117,122 |
| OzempicSemaglutide | 79 | $94,691 |
| JanuviaSitagliptin Phosphate | 71 | $74,168 |
| ProliaDenosumab | 37 | $61,330 |
| EliquisApixaban | 65 | $48,545 |
| TrulicityDulaglutide | 34 | $41,896 |
| GlyxambiEmpagliflozin/Linagliptin | 31 | $38,330 |
| InvokanaCanagliflozin | 30 | $29,234 |
| LinzessLinaclotide | 46 | $27,947 |
| TradjentaLinagliptin | 36 | $27,553 |
| MyrbetriqMirabegron | 38 | $26,962 |
| MounjaroTirzepatide | 22 | $20,995 |
| Icosapent Ethyl | 29 | $15,031 |
| EntrestoSacubitril/Valsartan | 19 | $14,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Tradjenta | $706 | $183,005178 claims |
| Novo NordiskOzempic | $1,242 | $94,69179 claims |
| MerckJanuvia | $286 | $74,16871 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $343 | $62,89156 claims |
| AmgenProlia | $172 | $61,33037 claims |
| PfizerEliquis | $134 | $48,54565 claims |
| AbbVieLinzess, Creon | $531 | $40,69860 claims |
| Johnson & JohnsonInvokana | $287 | $29,23430 claims |
| Astellas Pharma US IncMyrbetriq | $310 | $26,96238 claims |
| NovartisEntresto | $112 | $14,24919 claims |
| GSKAnoro Ellipta | $108 | $11,99227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Riverside
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.